A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.

Key facts

Study ID: NCT05556265
Run by: Bristol-Myers Squibb
People needed: 94
Starts: 2022-11-08
Expected to finish: 2024-05-16
Last updated by the study team: 2025-05-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Documented clinical diagnosis of alopecia areata (AA) for at least 6 months.
Current episode of scalp hair loss (at screening) must meet the following criteria: duration at least 6 months; duration of current hair loss episode of AA affecting ≥ 50% of the scalp not exceeding 8 years; scalp hair loss has been stable (no significant spontaneous regrowth [> 10%] over the last 6 months)
SALT score ≥ 50 at Screening and Day 1. Participant with complete scalp hair loss (SALT score of 100) with or without body hair involvement can be included.

You may not qualify if…

Participant with diffuse-type AA or other forms of hair loss, including traction alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, etc.
Other active skin diseases affecting the scalp that in the opinion of the investigator may interfere with accurate assessment of SALT score.
Extensive tattooing of the scalp that, in the opinion of the investigator, may interfere with the accurate assessment of SALT score.
Other protocol-defined inclusion/exclusion criteria apply.

Where it is running

Local Institution - 0016 — Santa Monica, California, United States
Local Institution - 0036 — New Haven, Connecticut, United States
Local Institution - 0018 — Tampa, Florida, United States
Local Institution - 0023 — Clinton Township, Michigan, United States
Local Institution - 0024 — New York, New York, United States
Local Institution - 0019 — Chapel Hill, North Carolina, United States
Local Institution - 0011 — Portland, Oregon, United States
Local Institution - 0032 — Pittsburgh, Pennsylvania, United States
Local Institution - 0012 — Austin, Texas, United States
Local Institution - 0013 — Houston, Texas, United States
Local Institution - 0014 — San Antonio, Texas, United States
Local Institution - 0017 — South Jordan, Utah, United States
Local Institution - 0003 — Kogarah, New South Wales, Australia
Local Institution - 0005 — Carlton, Victoria, Australia
Local Institution - 0015 — Winnipeg, Manitoba, Canada
Local Institution - 0021 — Markham, Ontario, Canada
Local Institution - 0009 — Peterborough, Ontario, Canada
Local Institution - 0010 — Richmond Hill, Ontario, Canada
Local Institution - 0034 — Montreal, Quebec, Canada
Local Institution - 0027 — Québec, Quebec, Canada
Local Institution - 0033 — Nice, France
Local Institution - 0020 — Paris, France
Local Institution - 0031 — Hamamatsu, Japan
Local Institution - 0028 — Kōtoku, Japan
Local Institution - 0030 — Mitaka-Shi, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.